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ABSTRACT
Purpose. Following the demonstrated efficacy and safety of
eribulin mesylate in heavily pretreated patients with meta-
static breast cancer, an exploratory analysis was performed to
investigate the effect of age in these patients.
Methods. Data were pooled from two single-arm phase II
studiesandoneopen-label randomizedphase III study inwhich
patients received eribulin mesylate at 1.4 mg/m2 as 2- to 5-
minute intravenous infusions ondays 1 and 8of a 21-day cycle.
The effect of age onmedian overall survival (OS), progression-
free survival (PFS), overall response rate (ORR), clinical
benefit rate (CBR), and incidence of adverse events (AEs) was
calculated for four age groups (,50 years, 50–59 years, 60–69
years,$70 years).
Results. Overall, 827 patients were included in the analysis
(,50 years, n 5 253; 50–59 years, n 5 289; 60–69 years,
n5 206;$70 years, n5 79). Age had no significant impact on
OS (11.8months, 12.3months, 11.7months, and12.5months,
respectively;p5 .82), PFS (3.5months, 2.9months, 3.8months,
and 4.0 months, respectively; p 5 .42), ORR (12.7%, 12.5%,
6.3%, and 10.1%, respectively), or CBR (20.2%, 20.8%, 20.4%,
and 21.5%, respectively). Although some AEs had higher in-
cidence in either the youngest or the oldest subgroup, there
was no overall effect of age on the incidence of AEs (including
neuropathy, neutropenia, and leukopenia).
Conclusion. Eribulin monotherapy in these selected older
patientswith goodbaseline performance status led toOS, PFS,
ORR, CBR, and tolerability similar to those of younger patients
withmetastatic breast cancer.Thebenefits and risks oferibulin
appear to be similar across age groups. The Oncologist 2014;
19:318–327
Implications for Practice: Although metastatic breast cancer (MBC) affects women of all ages, the use of sequential single-agent
chemotherapy treatment in patients with hormone-refractory MBC can be particularly challenging in the elderly because of
patient comorbidities and functional deficits. There is a major unmet need to find new, effective therapies with favorable safety
profiles forolderpatients.This exploratoryanalysis ofpooleddata fromselectedolderpatientswithpretreatedMBC inphase II and
III clinical trials showed similar efficacy and tolerability for eribulin among patients who were 70 years of age or older when
comparedwith younger patient subgroups.These data indicate that eribulinmaybe an effective option for selected older patients
with MBC.
INTRODUCTION
Breast cancer is largely a disease of older women. In the U.S.,
the median age at diagnosis is approximately 61 years [1],
andmost deaths occur inwomen aged 65 years and older [2].
The probability of a woman developing invasive breast can-
cer within the next 10 years increases from 0.06% for a 20-
year-oldto3.74%fora70-year-old [1,3].Owingto increased life
expectancy in developed countries, the lifetime risk of being
diagnosed with breast cancer is also increasing [1], under-
scoring the need for effective therapies in older patients.
Metastatic breast cancer (MBC) is incurable, so the goals of
treatment are to control symptoms, to improve or maintain
quality of life, and to prolong survival. However, few agents
have demonstrated an overall survival (OS) benefit in the
metastatic setting, and the optimal treatment sequence has
yet to be established [1, 4]. Consequently, themedian OS time
forpatientswithMBChasnot improvedmuch in the lastdecade
and is still between 2 years and 3 years when all subtypes are
considered together [5, 6]. For the majority of patients,
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sequential use of single chemotherapeutic agents represents
thebest strategy if patients areor become refractory to endocrine
therapy [7]. For older patients, comorbidities and functional
deficits can complicate chemotherapy, resulting in increased
toxicity and further loss of function [8–10]. Consequently,
there is an unmet need among older patients for therapies
that demonstrate efficacy and a favorable safety profile [11].
In particular, there is generally a lack of evidence to support
the use of currently available chemotherapeutic agents in
older patients with pretreated MBC.
Eribulin mesylate (E7389, Halaven; Eisai Inc., Woodcliff
Lake, NJ, http://www.halaven.com) is a structurally modified
synthetic analog of halichondrin B, a natural product isolated
from the marine sponge Halichondria okadai [12]. Eribulin is
a nontaxane microtubule inhibitor with a novel mode of
action distinct from other tubulin-targeting agents such as
paclitaxel [13–15]. Preclinical studies have indicated that
eribulin has antitumor activity in cell lines resistant to
paclitaxel and induces less neuropathy than paclitaxel or
ixabepilone [16, 17].
Eribulin has recently been granted approval as mono-
therapy in several countries globally based in part on the
results of thephase III EribulinMonotherapyVersus Treatment
of Physician’sChoice inPatientsWithMetastaticBreast Cancer
(EMBRACE) study in patients with heavily pretreated locally
recurrent breast cancer orMBC [18]. In this large, randomized
clinical trial, eribulin demonstrated a significant improvement
in median OS of 2.7 months compared with treatment of
physician’s choice (TPC) (hazard ratio: 0.81; 95% confidence
interval: 0.68–0.96; nominal p 5 .014) [18]. In addition, two
phase II clinical trials (Study 201 [19] and Study 211 [20]) of
eribulin in heavily pretreated patients with locally advanced
breast cancer or MBC demonstrated therapeutic activity and
a manageable tolerability profile. Across all age groups for
patients treated with eribulin in Study 201, Study 211, and
EMBRACE, respectively, OS was 9.0months, 10.4months, and
13.2months andprogression-free survival (PFS)was 2.6months,
2.6months, and 3.7months [18–20]. Objective response rates
(ORRs) were 11.5%, 9.3%, and 12% for Study 201, Study 211,
and EMBRACE, respectively, and clinical benefit rates (CBRs)
were 17.2%, 17.1%, and 23%, respectively [18–20].
Owing to the observed efficacy of eribulin in heavily pre-
treated patients with MBC, this exploratory analysis was con-
ducted to determinewhether similar therapeutic benefits and
tolerability profiles were observed among female patients 70
years and older versus younger patient cohorts using pooled
data from these three clinical trials [18–20].
METHODS
Study Design and Patients
Full descriptions of the individual study designs and patient
inclusionandexclusioncriteriahavebeenpublishedpreviously
[18–20]. All three studies enrolled female patients ($18 years)
with histologically or cytologically confirmed breast cancer
who had measurable and/or evaluable metastatic disease, an
Eastern Cooperative Oncology Group (ECOG) performance
status of 0–2 (0–1 for Study 201), and life expectancy of$3
months. All patients provided written informed consent
beforeundergoingany study-specific procedures.The studies
were conducted in accordance with the Declaration of
Helsinki, and approval was obtained from the relevant ethics
committees.
The EMBRACE trial (ClinicalTrials.gov identifier NCT00388726)
was a phase III, open-label, randomized, global, multicenter
study of eribulin versus TPC (any single-agent chemotherapy,
approved hormonal or biologic treatment, radiotherapy, or
symptomatic treatment alone) involving patients with heavily
pretreated locally recurrent breast cancer or MBC, with pre-
vious treatment including an anthracycline and a taxane. Pa-
tients with pre-existing grade.2 neuropathy were excluded.
The primary endpoint was OS; secondary endpoints included
PFS, ORR, and tolerability [18].
Study 201 (ClinicalTrials.gov identifier NCT00097721) was
a phase II, open-label, single-arm study involving patientswith
MBC who had received prior treatment that included at least
an anthracycline and a taxane [19]. Study 211 (ClinicalTrials.
gov identifierNCT00246090)was aphase II, open-label, single-
arm,multicenter study involving patientswith locally advanced
breastcancerorMBCpreviously treatedwithananthracycline,
taxane, and capecitabine [20]. For both studies, patients had
documented progression on chemotherapy orwithin 6months
of their last chemotherapy, and patients with pre-existing
grade .2 neuropathy were excluded [19, 20]. The primary
endpoint for both studies was ORR; secondary endpoints in-
cluded duration of response, PFS, OS, and tolerability [19, 20].
In all three studies, eribulinmesylate at 1.4mg/m2 (equivalent
to eribulin at 1.23 mg/m2) was administered intravenously
over 2–5 minutes on days 1 and 8 of a 21-day cycle. In Study
201, eribulinmesylate at 1.4mg/m2was initially administered
intravenouslyover2–5minutesondays1, 8, and15of a28-day
cycle [19]; however, owing to the incidence of neutropenia,
the dosing schedule was amended to days 1 and 8 of a 21-day
cycle, and only patients who received the 21-day dosing
schedule have been included in this analysis.
A CONSORT diagram representing the patients included
in the present analysis is depicted in Figure 1.
Exploratory Analysis
Data from these three studieswere pooled and compared across
four age cohorts based on patient age at study recruitment:
,50 years, 50–59 years, 60–69 years, and$70 years. OS and
PFS were analyzed using a Cox proportional hazards model
with 1 degree of freedom. OS was defined from the date
of randomization to death from any cause or last known date
alive (censored). PFS was defined from the date of randomi-
zation to the earliest date of disease progression or death
from any cause or was censored (as for OS).
ORR, defined as complete response (CR) plus partial
response (PR), and CBR, defined as CR plus PR plus stable
disease $6 months, were analyzed using the Cochran-Mantel-
Haenszel test.
Categoricalmodelcovariateswereappliedusingastepwise
model-selectionprocess (entry,p# .20, and removal,p. .05).
Categorical covariates that were considered during the selection
process in addition to age were race; prior vinorelbine treatment;
prior capecitabine treatment; refractory to anthracycline, taxane,
and capecitabine (defined as those who progressed on therapy
or within 6 months of receiving the therapy); number of total
prior chemotherapy regimens (#3 vs. .3); number of prior
www.TheOncologist.com ©AlphaMed Press 2014
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chemotherapy regimens for metastatic disease (#3 vs. .3);
hormone receptor status (ER, PGR); HER-2/neu status; triple-
negative tumor status (ER-negative/PGR-negative/HER-2/
neu-negative); and tumor stage at initial diagnosis.
A further sensitivity analysis fitted age, baseline body surface
area (BSA), andbaseline ECOGperformance status as continuous
covariates with stratification similar to the primary analysis.
Adverseevents (AEs)were summarized foreachagecohort
according to National Cancer Institute Common Terminology
Criteria for Adverse Events (version 3.0). Treatment-related
AEs of special interest included asthenia or fatigue, peripheral




treatment cycle andwere included in this pooled analysis (Table 1).
Of these,253patients (30.6%)were,50yearsold,289 (34.9%)
were 50–59 years old, 206 (24.9%) were 60–69 years old,
and 79 (9.6%) were$70 years old. Baseline demographic char-
acteristics were balanced between the age groups, although a
smaller proportion of patients in the $70 years subgroup ex-
hibited ECOG performance scores of 0 compared with the other
age groups (20.3% vs. 42.6%–47.8%) (Table 1).
Efficacy
Overall Survival
For the cohorts of patients aged ,50 years, 50–59 years,
60–69 years, and$70 years, median OS was 11.8 months, 12.3
months, 11.7 months, and 12.5 months, respectively (p5 .82)
(Fig. 2A, Table 2). No relationship was observed between age
and OS when analyzed by cohort or as a continuous variable
(Table 3). Of the clinical variables examined, those that had
a significant impact favoring improvedOSwerehaving threeor
more prior chemotherapy regimens, not being refractory to
taxane therapy, and having an ER-positive tumor. In the sen-
sitivity analyses using continuous covariates, higher BSA and
better baseline ECOG performance status also predicted
improved OS (Table 3).
Progression-Free Survival
For thecohortsofpatientsaged,50years,50–59years,60–69
years, and$70years,medianPFSassessedby independent re-
viewwas3.5months, 2.9months, 3.8months, and4.0months,
respectively (p 5 .42) (Fig. 2B, Table 2). PFS assessed by in-
vestigators was similar (data not shown). No significant dif-
ferences in PFS were observed between the four age cohorts
(Table3).ComparablePFSresultswerealsoobtainedwhenage
was fitted as a continuous variable (data not shown). Clinical
categorical variables that had a favorable impact on PFS as
determined by independent review were not being refractory
to capecitabine therapy and having an ER-positive tumor;
higher baseline BSA and better baseline ECOG performance
status also favored longer PFS (Table 3).
ORR and CBR
Age did not have a significant impact on either ORR (inde-
pendent or investigator assessed) or CBR (Table 2). Positive ER
status and higher baseline BSA were the only significant pre-
dictors of both ORR and CBR improvement (Table 3).
Figure 1. CONSORT diagram. Reprinted with permission from©2010 American Society of Clinical Oncology (Cortes J, et al.: J Clin Oncol
Vol.28,2010:3922–3928).All rights reserved.Reprinted fromTheLancet,Vol.377,Cortes J, etal., EribulinMonotherapyVersusTreatment
of Physician’s Choice in Patients With Metastatic Breast Cancer (EMBRACE): A phase 3 open-label randomised study, pages 914–923, ©
2011, with permission from Elsevier.
Abbreviations: RECIST, Response Evaluation Criteria in Solid Tumors, TCP, treatment of physician’s choice.
©AlphaMed Press 2014
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Safety
Compared with the overall population, a similar proportion of
patients within the different age cohorts experienced at least
one AE of any grade (,50 years, 98.8%; 50–59 years, 99.3%;
60–69 years, 99.0%; $70 years, 100%). The numbers of pa-
tients reporting one treatment-relatedAEormore (,50years,
94.9%; 50–59 years, 95.8%; 60–69 years, 96.6%; $70 years,
93.7%) or one serious AE or more (,50 years, 28.5%; 50–59
years, 24.6%; 60–69 years, 29.6%;$70years, 25.3%)werealso
comparable between the age cohorts. However, AEs leading
to dose reduction, delay, or discontinuation increased slightly
with age (,50 years, 45.8%; 50–59 years, 49.8%; 60–69 years,
51.5%;$70 years, 51.9%). An analysis comparing the cohorts
aged,50 years, 50–59 years, and 60–69 yearswith the cohort
aged$70 years showed no significant differences in the odds
ratios for theoccurrenceofadverseevents leadingtodosedelays,
reductions, or withdrawal from treatment (data not shown).
Nodifferences in concomitant useofgrowth factors during
the study were observed between age groups (granulocyte
colony-stimulating factor: ,50 years, 6.0%; 50–59 years, 8.1%;
Table 1. Patient demographics and baseline characteristics
Characteristic





























128 (25.4) 0 0 128 (15.5) 50 (19.8) 42 (14.5) 30 (14.6) 6 (7.6)
Latin America/
South Africa
53 (10.5) 0 0 53 (6.4) 21 (8.3) 18 (6.2) 12 (5.8) 2 (2.5)
ECOG performance
status
0 222 (44.1) 18 (54.5) 108 (37.1) 348 (42.1) 121 (47.8) 123 (42.6) 88 (42.7) 16 (20.3)
1 242 (48.1) 15 (45.5) 165 (56.7) 422 (51.0) 117 (46.2) 151 (52.2) 100 (48.5) 54 (68.4)
2 37 (7.4) 0 17 (5.8) 54 (6.5) 15 (5.9) 13 (4.5) 17 (8.3) 9 (11.4)
Unknown 2 (0.4) 0 1 (0.3) 3 (0.4) 0 2 (0.7) 1 (0.5) 0
HER2/neu positivea 83 (16.5) 5 (15.2) 31 (10.7) 119 (14.4) 37 (14.6) 50 (17.3) 21 (10.2) 11 (13.9)
ER and/or PGR
positive
324 (64.4) 18 (54.5) 189 (64.9) 531 (64.2) 155 (61.3) 189 (65.4) 131 (63.6) 56 (70.9)
ER, PGR, and HER2/
neu negativea




1 1 (0.2) 2 (6.1) 1 (0.3) 4 (0.5) 1 (0.4) 3 (1.0) 0 0
2 65 (12.9) 4 (12.1) 30 (10.3) 99 (12.0) 30 (11.9) 33 (11.4) 25 (12.1) 11 (13.9)
3 175 (34.8) 7 (21.2) 83 (28.5) 265 (32.0) 90 (35.6) 80 (27.7) 72 (35.0) 23 (29.1)
$4 260 (51.7) 20 (60.6) 177 (60.8) 457 (55.3) 131 (51.8) 172 (59.5) 109 (52.9) 45 (57.0)
Prior chemotherapyb
Capecitabine 367 (73.0) 23 (69.7) 291 (100.0) 681 (82.3) 212 (83.8) 234 (81.0) 169 (82.0) 66 (83.5)
Gemcitabine 130 (25.8) 19 (57.6) 91 (31.3) 240 (29.0) 84 (33.2) 70 (24.2) 62 (30.1) 24 (30.4)
Vinorelbine 201 (40.0) 14 (42.4) 113 (38.8) 328 (39.7) 94 (37.2) 120 (41.5) 78 (37.9) 36 (45.6)
Refractory to:c
Taxane 277 (55.1) 19 (57.6) 147 (50.5) 443 (53.6) 141 (55.7) 148 (51.2) 113 (54.9) 41 (51.9)
Capecitabine 290 (57.7) 17 (51.5) 232 (79.7) 539 (65.2) 172 (68.0) 193 (66.8) 121 (58.7) 53 (67.1)
Anthracycline 149 (29.6) 14 (42.4) 60 (20.6) 223 (27.0) 68 (26.9) 74 (25.6) 54 (26.2) 27 (34.2)
All data are number of patients (percentage) unless otherwise stated.
aCombined fluorescence in situ hybridization and immunohistochemistry results from local laboratory testing.
bAll patients had received prior anthracycline and taxane therapy as per inclusion criteria.
c”Refractory”was defined as those who progressed on or within 6 months of receiving the therapy.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EMBRACE, Eribulin Monotherapy Versus Treatment of Physician’s Choice in Patients With
Metastatic Breast Cancer.
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60–69 years, 5.2%; $70 years, 2.1%; erythropoiesis-stimulating
agent:,50years,5.4%;50–59years,6.9%;60–69years,4.2%;$70
years, 2.9%).
Most AEs (all grades) displayed similar prevalence among
the different age cohorts (Table 4).The incidences of alopecia,
dyspnea, and peripheral neuropathy were similar across the
differentagecohorts, aswere the rates forneutropenia, febrile
neutropenia, and leukopenia (Table 4; data not shown). Certain
AEshadhigher incidence inolderpatients comparedwithyounger
patients, including asthenia or fatigue (,50 years, 54.9%;$70
years, 70.9%), peripheral edema (,50 years, 5.5%;$70 years,
19.0%), and dizziness (,50 years, 5.9%; $70 years, 12.7%)
(Table 4; data not shown). Nausea (,50 years, 40.7%; $70
years,22.8%)andvomiting (,50years,23.7%;$70years,11.4%)
tended to be more common in the youngest cohort (Table 4).
Similar incidences of grade 3/4 AEs were experienced across
the age cohorts and in comparisonwith the overall population
(Table 4). Treatment-related deaths were reported for five
patients in the cohort aged 50–59 years (febrile neutropenia,
lung infection, bronchopneumonia, dyspnea, and unknown)
and for one patient in the cohort aged 60–69 years (dyspnea).
Similar incidences of each treatment-related AE of special
interest (asthenia or fatigue, peripheral neuropathy, nausea,
arthralgia ormyalgia, and vomiting) were reported among the
different age cohorts (Table 5). However, some differences
were observed in grade 3/4 treatment-related AEs in older
Figure 2. Kaplan-Meier graph of overall survival (A) and progression-free survival (B) by independent review.
Abbreviation: CI, confidence interval.
Table 2. Efficacy outcomes by age cohort
Age at recruitment (years)
Intent-to-treat population Response-evaluable population
n Median OS (months) n Median PFS (months) ORR (%) CBR (%)
,50 253 11.8 234 3.5 12.7 20.2
50–59 289 12.3 262 2.9 12.5 20.8
60–69 206 11.7 195 3.8 6.3 20.4
$70 79 12.5 75 4.0 10.1 21.5
Abbreviations: CBR, clinical benefit rate; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
©AlphaMed Press 2014
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patients comparedwith those in the younger cohort. Of these,
asthenia or fatigue (,50 years, 5.9%;$70 years, 13.9%) and
peripheral neuropathy (,50 years, 4.0%; $70 years, 10.1%)
were more frequent in the oldest cohort (Table 5).
DISCUSSION
In this patient population that was fit enough to be eligible for
clinical trials, eribulin monotherapy showed similar benefits
among all age cohorts. Importantly, efficacy benefits were
achieved in all age groups associated with a manageable
tolerability profile; toxicity appeared to be no greater in older
patients. There were some differences in the incidences of
individual AEs among the different age cohorts, suggesting
that clinical judgment should play a key role in predicting the
effect of age on toxicity, particularly in relation to any pre-
existing comorbidity. Implementation of geriatric assessment
Table 3. Multivariate analysis of efficacy and OS with age as continuous covariate
Variable HR/ORa 95% CI p value
OSb
Age (,50 vs. 50–59 years) 1.18 (0.92–1.51) .199
Age (60–69 vs. 50–59 years) 1.19 (0.92–1.55) .196
Age ($70 vs. 50–59 years) 0.81 (0.55–1.19) .278
ER status (negative vs. positive) 1.48 (1.19–1.85) .001
Baseline BSAc 0.45 (0.25–0.81) .008
Baseline ECOG performance statusc 1.68 (1.41–2.01) .000
Taxane refractory (no vs. yes) 0.71 (0.58–0.88) .001
Number of prior chemotherapy regimens (£3 vs..3) 0.73 (0.59–0.90) .004
OSb
Agec 1.00 (0.99–1.01) .448
ER status (negative vs. positive) 1.42 (1.13–1.80) .003
Baseline ECOG performance statusc 1.66 (1.38–1.99) .000
Taxane refractory (no vs. yes) 0.67 (0.54–0.84) ,.001
Previous vinorelbine status (no vs. yes) 0.75 (0.60–0.93) .008
Anthracycline refractory (no vs. yes) 0.78 (0.61–0.99) .0413
PFSb
Age (,50 vs. 50–59 years) 1.08 (0.87–1.35) .466
Age (60–69 vs. 50–59 years) 0.88 (0.70–1.11) .272
Age ($70 vs. 50–59 years) 0.81 (0.58–1.14) .233
ER status (negative vs. positive) 1.44 (1.18–1.75) ,.001
Baseline BSAc 0.43 (0.26–0.71) .001
Baseline ECOG performance statusc 1.23 (1.06–1.42) .006
Capecitabine refractory (no vs. yes) 0.80 (0.66–0.98) .032
ORRd
Age (,50 vs. 50–59 years) 1.12 (0.72–1.73) .622
Age (60–69 vs. 50–59 years) 0.65 (0.36–1.10) .127
Age ($70 vs. 50–59 years) 1.07 (0.53–1.96) .832
ER status (negative vs. positive) 0.41 (0.25–0.61) ,.001
Baseline BSAc 5.98 (1.45–24.24) .012
CBRd
Age (,50 vs. 50–59 years) 0.89 (0.63–1.25) .510
Age (60–69 vs. 50–59 years) 1.07 (0.74–1.52) .730
Age ($70 vs. 50–59 years) 0.97 (0.57–1.58) .920
ER status (negative vs. positive) 0.62 (0.48–0.79) ,.001
Baseline BSAc 7.03 (2.34–21.30) .001
Bold text indicates comparator group and corresponding p value associated with significance.
aHR was used for OS and PFS, OR was used for ORR and CBR.
bOS and PFS were analyzed by Cox proportional hazards model using the chi-square test.
cFitted as a continuous covariate.
dORR and CBRwere analyzed using logistic regressionmodel usingWald’s chi-square test. All used 1 degree of freedom.Model covariates were selected
usingastepwisemodel selectionprocess (entryp .20, removalp. .05).PFSandclinical responsesweredeterminedby independent review; forcomplete/
partial responses, if a patient was not independently reviewed, then the investigators’ assessment was used for Study 201 and 211 in cases in which
patients progressed on or before cycle 2 assessment.
Abbreviations: BSA, body surface area; CBR, clinical benefit rate; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio;
PFS, progression-free survival; OR, odds ratio; ORR, overall response rate; OS, overall survival.
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Table 4. Overall adverse events in each age cohort with an incidence of.20% (all grades) or.5% (grade 3/4) in any cohort
Adverse event <50 years (n5 253) 50–59 years (n5 289) 60–69 years (n5 206) ‡70 years (n5 79) Total (N5 827)
Blood and lymphatic system disorders
Neutropenia
All grades 126 (49.8) 164 (56.7) 122 (59.2) 45 (57.0) 457 (55.3)
Grade 3/4 111 (43.9) 145 (50.2) 109 (52.9) 39 (49.4) 404 (48.9)
Anemia
All grades 52 (20.6) 60 (20.8) 54 (26.2) 21 (26.6) 187 (22.6)
Grade 3/4 4 (1.6) 6 (2.1) 5 (2.4) 2 (2.5) 17 (2.1)
Leukopenia
All grades 52 (20.6) 70 (24.2) 46 (22.3) 18 (22.8) 186 (22.5)
Grade 3/4 32 (12.6) 41 (14.2) 33 (16.0) 10 (12.7) 116 (14.0)
Gastrointestinal disorders
Nausea
All grades 103 (40.7) 131 (45.3) 77 (37.4) 18 (22.8) 329 (39.8)
Grade 3/4 5 (2.0) 7 (2.4) 3 (1.5) 1 (1.3) 16 (1.9)
Constipation
All grades 66 (26.1) 82 (28.4) 62 (30.1) 19 (24.1) 229 (27.7)
Grade 3/4 2 (0.8) 3(1.0) 2(1.0) 0 7 (0.8)
Vomiting
All grades 60 (23.7) 58 (20.1) 43 (20.9) 9 (11.4) 170 (20.6)
Grade 3/4 5 (2.0) 3 (1.0) 3 (1.5) 0 11 (1.3)
Diarrhea
All grades 43 (17.0) 55 (19.0) 52 (25.2) 15 (19.0) 165 (20.0)
Grade 3/4 0 4 (1.4) 1 (0.5) 1 (1.3) 6 (0.7)
General disorders
Asthenia/fatigue
All grades 139 (54.9) 171 (59.2) 129 (62.6) 56 (70.9) 495 (59.9)
Grade 3/4 17 (6.7) 26 (9.0) 24 (11.7) 13 (16.5) 80 (9.7)
Pyrexia
All grades 65 (25.7) 61 (21.1) 55 (26.7) 17 (21.5) 198 (23.9)
Grade 3/4 0 3 (1.0) 2 (1.0) 0 5 (0.6)
Metabolism and nutrition disorders
Decreased appetite
All grades 52 (20.6) 78 (27.0) 55 (26.7) 21 (26.6) 206 (24.9)
Grade 3/4 0 0 0 0 0
Musculoskeletal and connective tissue disorders
Arthralgia/myalgia
All grades 61 (24.1) 67 (23.2) 43 (20.9) 21 (26.6) 192 (23.2)
Grade 3/4 3 (1.2) 2 (0.7) 3 (1.5) 0 8 (1.0)
Nervous system disorders
Peripheral neuropathya
All grades 105 (41.5) 110 (38.1) 93 (45.1) 35 (44.3) 343 (41.5)
Grade 3/4 12 (4.7) 22 (7.6) 21 (10.2) 8 (10.1) 63 (7.6)
Headache
All grades 62 (24.5) 62 (21.5) 31 (15.0) 14 (17.7) 169 (20.4)
Grade 3/4 4 (1.6) 1 (0.3) 1 (0.5) 0 6 (0.7)
Respiratory, thoracic, and mediastinal disorders
Dyspnea
All grades 38 (15.0) 53 (18.3) 36 (17.5) 17 (21.5) 144 (17.4)
Grade 3/4 9 (3.6) 9 (3.1) 12 (5.8) 5 (6.3) 35 (4.2)
Skin and subcutaneous tissue disorders
Alopeciab
120 (47.4) 148 (51.2) 108 (52.4) 41 (51.9) 417 (50.4)All grades
Data are number of patients (percentage).
aPeripheral neuropathy based on broad standardized Medical Dictionary for Regulatory Activities queries and includes neuropathy peripheral,
neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy, peripheral sensorimotor neuropathy, demyelinating
polyneuropathy, and paresthesia.
bAlopecia is recorded as grade 1 or 2 only.
©AlphaMed Press 2014
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tools in cancer trials, such as that evaluated in the recent
Cancer and Leukemia Group B (CALG-B) 360401 study, may
assist in identifying factors that contribute to morbidity and
mortality in older patients and, in turn, help establish
treatment recommendations [21]. In this analysis, most
patients had normal or mild declines in performance status
prior to trial entry, and the effectiveness of chemotherapy in
patients with functional deficits is uncertain, particularly in
older populations.
A limitation of this analysis is that the patients were
enrolled in clinical trials with stringent entry criteria. Many of
the elderly patients in this analysis had previously received mul-
tiple lines of chemotherapy, and thus the studied population
maymanifest above-average fitness in termsof chemotherapy
tolerance. Although this study included a substantial number
of older adults with heavily pretreated MBC—approximately
10% (79 of 827patients) who were aged $70 years—only a
large prospective study including prospectively performed
geriatric assessments would more precisely define the effi-
cacy and tolerability of eribulin in older patients.
Establishing the optimal treatment strategy for older pa-
tients with breast cancer is challenging, and this is highlighted
by the fact that although the overall mortality rate for patients
with breast cancer has generally decreased, this outcome has
not been achieved equally across age groups [22–24]. Using
data fromNationalVital StatisticsReports spanning1990–2007,
Smith et al. recently showed that although the 10-year
absolute riskofbreastcancerdeathhasdecreasedby15.3%for
women aged 50–64 years, this risk has been reduced by only
7.5% forwomen aged$75 years [24].Thismay, in part, be due
to the observation that effective screening and treatments
are less likely to be offered to older women. Moreover, prior
exclusion of older patients from clinical trials and poor accrual
of older, eligible patients to more current trials limits our
knowledge concerning optimal therapy for older patients.
Consequently, appropriate and effective therapy may be un-
derused in older women because of concerns about the
potential complications caused by multiple comorbidities as
well as the potential for increased toxicity [11, 25, 26].
In line with the results of this study, other retrospective
analyses of the benefits of chemotherapy in MBC have also
shown no detrimental interaction of age and outcome in
generally fit patients [2]. CALG-B showed that the efficacy of
paclitaxel (80 mg/m2 weekly vs. 175 mg/m2 every 3 weeks) in
1,048 older patients with MBC was not related to age group
(,55 years, 55–64 years, and $65 years) [27]; better
performance status and first-line therapy were associated
with greater treatment benefit. However, the incidence of
grade 3 neurotoxicity increased with age, with the shortest
time to onset seen in patients aged $65 years receiving
paclitaxel as second-line treatment.
Similar results were observed in a retrospective analysis of
two EuropeanOrganization for Research and Treatment of Cancer
trials involving pegylated liposomal doxorubicin administered
at either 60mg/m2 every 6 weeks or 50mg/m2 every 4 weeks
to older patients with MBC (48% [65 of 136] of patients were
aged$70 years). Efficacy outcomes were not affected by age;
however, the incidences of hematologic toxicity, anorexia, asthenia,
and stomatitis were higher for older patients compared with
younger patients who received the 6-week schedule but not
the 4-week schedule [28].
The effect of age on capecitabine effectiveness has also
been investigated recently in patients with MBC. The pooled
results of five phase II/III pivotal trials of capecitabine (mono-
therapy or combination therapy) in 570 patients showed that
OS, CBR or ORR, and the incidence of AEs were not related to
age (cohorts were aged 18–49 years, 50–64 years, and $65
years) [29]. However,womenaged$65 yearsweremore likely
to withdraw from treatment because of an AE [29]. A recent
reviewof capecitabine in elderly patientswithMBC concluded
Table 5. Treatment-related adverse events of special interest in each age cohort
Adverse eventa <50 years (n5 253) 50–59 years (n5 289) 60–69 years (n5 206) ‡70 years (n5 79) Total (N5 827)
Asthenia/fatigue
All 125 (49.4) 150 (51.9) 115 (55.8) 47 (59.5) 437 (52.8)
Grade 3/4 15 (5.9) 20 (6.9) 21 (10.2) 11 (13.9) 67 (8.1)
Peripheral neuropathyb
All 77 (30.4) 84 (29.1) 74 (35.9) 30 (38.0) 265 (32.0)
Grade 3/4 10 (4.0) 21 (7.3) 18 (8.7) 8 (10.1) 57 (6.9)
Nausea
All 87 (34.4) 116 (40.1) 70 (34.0) 17 (21.5) 290 (35.1)
Grade 3/4c 1 (0.4) 4 (1.4) 3 (1.5) 1 (1.3) 9 (1.1)
Arthralgia/myalgia
All 38 (15.0) 36 (12.5) 26 (12.6) 7 (8.9) 107 (12.9)
Grade 3/4 0 0 3 (1.5) 0 3 (0.4)
Vomiting
All 48 (19.0) 40 (13.8) 26 (12.6) 6 (7.6) 120 (14.5)
Grade 3/4 1 (0.4) 1 (0.3) 2 (1.0) 0 4 (0.5)
Data are number of patients (percentage).
aNo grade 5 events.
bPeripheral neuropathy based on broad standardized Medical Dictionary for Regulatory Activities queries and includes neuropathy peripheral,
neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy, peripheral sensorimotor neuropathy, demyelinating
polyneuropathy, and paresthesia.
cNo grade 4 events.
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that capecitabine monotherapy is suitable for such patients
but that reductions from the labeled dose should be con-
sidered [22].
In a retrospective population-based analysis of women
aged$66 yearswhohad stage IVER-negativeMBC (n51,519;
33% had received chemotherapy), age did not affect the sig-
nificant survival benefit associated with chemotherapy [30].
Similarly, a recent review of retrospective evidence suggested
that although chemotherapy is probably more toxic in older pa-
tients with ER-negative MBC, they can derive the same benefits
from chemotherapy treatment as younger women [31]. The
association between higher BSA and better outcomes seen in
this study was unanticipated. A similar trend has also been
observed in an analysis of patients in a German cancer
registry [32] who received chemotherapy. Further analysis of
eribulin pharmacokinetic data may provide more insight
into these observations.
CONCLUSION
Our data show that eribulin monotherapy in older women
with MBC who are sufficiently fit to enter clinical trials leads
to similar response rates, times to progression, and OS ben-
efits as experienced those by younger patients. These data
are similar to retrospective analyses of other agents in this
setting and show that in generally fit patients, age is not
related to outcome. Of note, eribulin was used in heavily
treated patients and in the EMBRACE trial showed a sig-
nificant improvement in survival comparedwithother agents
routinely used in the metastatic setting. This survival advan-
tage, coupled with a manageable safety profile, demonstrates
that eribulin may be an effective option for selected older
patients with MBC.
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For Further Reading:
Willemien van deWater, Caroline Seynaeve, Esther Bastiaannet et al. Elderly Postmenopausal PatientsWith Breast Cancer
Are at Increased Risk for Distant Recurrence: A Tamoxifen Exemestane Adjuvant Multinational Study Analysis. The
Oncologist 2013;18:8–13.
Implications for Practice:
This studyanalyzed9,766postmenopausal breastcancerpatientswithhormone-sensitivediseasewhowere included in the
Tamoxifen ExemestaneAdjuvantMultinational (TEAM) trial.The authors demonstrated a higher incidence ofdistant breast
cancer recurrencewith increasing age atdiagnosis.Thus, the commonbelief that the clinical courseof breast cancer in older
women may be more indolent is rejected in this study. All patients received endocrine therapy, while radiotherapy after
breast-conserving surgery and administration of chemotherapy decreased with increasing age. As distant recurrence may
reflect underuse of systemic therapy, these findings hint at undertreatment of systemic therapy, and chemotherapy in
particular. Consequently, chemotherapy may be consideredmore often in relatively fit elderly breast cancer patients with
hormone-sensitive disease.
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